Pepstatin Ammonium
Based on 62 publication(s) in Google Scholar
Pepstatin (Pepstatin A) Ammonium is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.22%
- Formule: C34H66N6O9
- Masse moléculaire:702.92
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pepstatin Ammonium
More- Signal Transduct Target Ther. 2025 Dec 17;10(1):413. [Abstract]
- Nature. 2024 Aug;632(8025):686-694. [Abstract]
- Nature. 2024 Aug;632(8026):930-937. [Abstract]
- Cell. 2025 Nov 26;188(24):6861-6872.e14. [Abstract]
- Cell Res. 2026 Mar 16.
- Cell Res. 2025 May;35(5):385-388. [Abstract]
- Autophagy. 2026 May 7:1-17. [Abstract]
- Autophagy. 2025 Jul;21(7):1591-1607. [Abstract]
- Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]
- Nat Commun. 2025 Jul 16;16(1):6551. [Abstract]
- Nat Commun. 2025 Apr 2;16(1):3153. [Abstract]
- Nat Commun. 2025 Mar 11;16(1):2412. [Abstract]
- ACS Nano. 2024 Jul 2;18(26):16790-16807. [Abstract]
- ACS Nano. 2024 Jan 23;18(3):2162-2183. [Abstract]
- J Adv Res. 2026 May 21:S2090-1232(26)00436-4. [Abstract]
- Redox Biol. 2024 Apr:70:103064. [Abstract]
- Theranostics. 2024 Jul 22;14(11):4481-4498. [Abstract]
- Adv Sci (Weinh). 2026 May;13(25):e15367. [Abstract]
- Adv Sci (Weinh). 2025 Aug 7:e09208. [Abstract]
- Adv Sci (Weinh). 2023 Oct;10(28):e2302130. [Abstract]
- Adv Sci (Weinh). 2022 Oct 10;e2203831. [Abstract]
- Sci Adv. 2026 Jan 30;12(5):eadz8234. [Abstract]
- Sci Adv. 2022 Nov 11;8(45):eabn6579. [Abstract]
- Cell Death Differ. 2026 Jan 28. [Abstract]
- Carbohydr Polym. 2023 Nov 1:319:121208. [Abstract]
- Cell Death Dis. 2022 Dec 16;13(12):1048. [Abstract]
- Pharmacol Res. 2022 Jan:175:105985. [Abstract]
- Environ Sci Technol. 2017 Dec 5;51(23):13938-13948. [Abstract]
- Cancer Lett. 2026 Apr 1:642:218277. [Abstract]
- Cancer Lett. 2022 Jun 1:535:215629. [Abstract]
- Free Radic Biol Med. 2025 Apr 23:S0891-5849(25)00247-3. [Abstract]
- J Anim Sci Biotechnol. 2026 Mar 14;17(1):49. [Abstract]
- Cell Rep. 2025 Jan 15;44(1):115219. [Abstract]
- Cell Rep. 2021 Nov 2;37(5):109931. [Abstract]
- Br J Pharmacol. 2025 May;182(10):2310-2331. [Abstract]
- Int J Oncol. 2019 Jul;55(1):331-339. [Abstract]
- Pharmaceuticals (Basel). 2022 Dec 3;15(12):1509. [Abstract]
- Eur J Pharmacol. 2022 Apr 5:920:174823. [Abstract]
- Protein Sci. 2024 Dec;33(12):e5225. [Abstract]
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
- Mol Med Rep. 2019 Jan;19(1):41-50. [Abstract]
- PLoS Pathog. 2025 Oct 17;21(10):e1013581. [Abstract]
- Mol Pharm. 2024 May 9. [Abstract]
- PLoS Pathog. 2024 Feb 14;20(2):e1011981. [Abstract]
- Structure. 2025 Dec 4;33(12):2049-2057.e5. [Abstract]
- BBA Adv. 2026 May 16:9:100194. [Abstract]
- FASEB J. 2022 Jan;36(1):e22121. [Abstract]
- Immunotargets Ther. 2025 Mar 4:14:151-173. [Abstract]
- J Virol. 2023 Nov 30;97(11):e0107523. [Abstract]
- J Virol. 2021 Nov 23;95(24):e0153721. [Abstract]
- PLoS Genet. 2025 Jul 10;21(7):e1011794. [Abstract]
- Toxicol Appl Pharmacol. 2018 Oct 1;356:159-171. [Abstract]
- Arch Biochem Biophys. 2023 Jul 15:743:109646. [Abstract]
- Biochem Biophys Res Commun. 2024 Jun 15:725:150271. [Abstract]
- Biochem Bioph Res Co. 2020 Sep 10;530(1):292-300. [Abstract]
- Biol Pharm Bull. 2022 Apr 1;45(4):438-445. [Abstract]
- STAR Protoc. 2025 Jul 18;6(3):103963. [Abstract]
- bioRxiv. 2025 Dec 26.
- Maastricht University. 2025.
- bioRxiv. 2024 November 14.
- bioRxiv. 2023 Nov 5.
- SSRN. 2023 Apr 10.
Customer Validation & Images
-
Cell Imaging/Staining
-
WB
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
WB
Activité biologique
IC50: 4.5 nM (Hemoglobin-pepsin), 6.2 nM (Hemoglobin-proctase), 150 nM (Casein-pepsin), 260 nM (Hemoglobin-acid protease), 290 nM (Casein-proctase), 520 nM (Casein-acid protease)[1]
Pepstatin (Pepstatin A) (7 μM; 48 h) affects the intracellular processing of HIV-specific gag protein[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pepstatin (0.5-50 mg/kg, p.o.) suppresses stomach ulceration of the pylorus in ligated Shay rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pylorus ligated male Wistar rats[1]
-
Dosage:0.5, 1, 10 and 50 mg/kg
-
Administration:Oral administration, 15 minutes after pyloric ligation
-
Result:Effectively prevented stomach ulceration.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 702.92
-
Formule C34H66N6O9
-
Color White to off-white
-
Synonyms
Pepstatin A Ammonium
-
Structure Classification
-
Initial Source
Actinomyces
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (62)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]2025 Dec 17;10(1):413. PMID: 41407678 -
Nature
2024 Aug;632(8025):686-694. PMID: 39112701 -
Nature
2024 Aug;632(8026):930-937. PMID: 39085602 -
Cell
2025 Nov 26;188(24):6861-6872.e14. PMID: 41138730 -
-
Cell Res
Structural basis of augmenting taurine uptake by the taurine transporter in alleviating cellular senescence. [Abstract]2025 May;35(5):385-388. PMID: 40108449 -
Autophagy
2026 May 7:1-17. PMID: 42080372 -
Autophagy
2025 Jul;21(7):1591-1607. PMID: 39952286
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Jul;21(7):1591-1607. [Abstract]
Representative fluorescence image of tfLC3 under Pepstatin A + E64d condition in primary liver cells from tfLC3-KI mice.
-
Nat Commun
PRDX1 promotes testosterone synthesis and attenuates aging via redox regulation of ATG4B to modulate lipophagy. [Abstract]2025 Nov 19;16(1):10181. PMID: 41261096
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]
WB analyses of LC3 and p62 levels in cells after indicated treatments for 8 h. The relative levels of LC3 and p62 were showed. 3-MA (3-Methyladenine, 10 mM), CQ (Chloroquine, 20 μM), PA (Pepstatin A,10 μg/mL), LP (Leupeptin, 100 μM), Rapa (Rapamycin, 10 nM).
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]
Co-immunofluorescence of PRDX1 (red) and LC3 (green) in WT TM3 cells. Cells were treated with or without Chloroquine (20 μM), Pepstatin A (10 μg/mL), or Leupeptin (100 μM) for 8 hours.
-
Nat Commun
2025 Jul 16;16(1):6551. PMID: 40670375 -
Nat Commun
Molecular insights into the α6β4 nicotinic acetylcholine receptor function and ligand recognition. [Abstract]2025 Apr 2;16(1):3153. PMID: 40175361 -
Nat Commun
2025 Mar 11;16(1):2412. PMID: 40069141 -
ACS Nano
Realistic Nanoplastics Induced Pulmonary Damage via the Crosstalk of Ferritinophagy and Mitochondrial Dysfunction. [Abstract]2024 Jul 2;18(26):16790-16807. PMID: 38869479 -
ACS Nano
Ligand Phase Separation-Promoted, "Squeezing-Out" Mode Explaining the Mechanism and Implications of Neutral Nanoparticles That Escaped from Lysosomes. [Abstract]2024 Jan 23;18(3):2162-2183. PMID: 38198577 -
J Adv Res
Targeting myofibroblast copper vulnerability reverses pulmonary fibrosis via METTL3-directed STAT6 m6A driving cuproptosis. [Abstract]2026 May 21:S2090-1232(26)00436-4. PMID: 42173361 -
Redox Biol
SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis. [Abstract]2024 Apr:70:103064. PMID: 38320455 -
Theranostics
Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy. [Abstract]2024 Jul 22;14(11):4481-4498. PMID: 39113807 -
Adv Sci (Weinh)
Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation. [Abstract]2026 May;13(25):e15367. PMID: 41722054 -
Adv Sci (Weinh)
2025 Aug 7:e09208. PMID: 40776529 -
Adv Sci (Weinh)
Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2. [Abstract]2023 Oct;10(28):e2302130. PMID: 37544908 -
Adv Sci (Weinh)
The Endoplasmic Reticulum ATP13A1 is Essential for MAVS-Mediated Antiviral Innate Immunity. [Abstract]2022 Oct 10;e2203831. PMID: 36216581
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Oct 10;e2203831. [Abstract]
Wild-type and ATP13A1−/− HEK293T cells were treated with Bafilomycin A1 (200 nM), E-64d (10 µg/mL) or Pepstatin A (10 µg/mL) for 12 h before immunoblotting analysis.
-
Sci Adv
Structural insight into the glucose-6-phosphate transport by G6PT1 and inhibition mechanism of CGA. [Abstract]2026 Jan 30;12(5):eadz8234. PMID: 41616054 -
Sci Adv
Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. [Abstract]2022 Nov 11;8(45):eabn6579. PMID: 36351019 -
Cell Death Differ
TUFT1 stabilizes TGF-β receptor II protein and facilitates activation of hepatic stellate cells into metastasis-promoting myofibroblasts. [Abstract]2026 Jan 28. PMID: 41593321 -
Carbohydr Polym
Agrocybe cylindracea fucoglucogalactan induced lysosome-mediated apoptosis of colorectal cancer cell through H3K27ac-regulated cathepsin D. [Abstract]2023 Nov 1:319:121208. PMID: 37567726
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Carbohydr Polym. 2023 Nov 1:319:121208. [Abstract]
The viability of HCT-116 cells pretreated with 5 μM Pepstatin A was detected by CCK8.
-
Cell Death Dis
Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein. [Abstract]2022 Dec 16;13(12):1048. PMID: 36526614 -
Pharmacol Res
Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy. [Abstract]2022 Jan:175:105985. PMID: 34863821 -
Environ Sci Technol
Determining the Cytotoxicity of Rare Earth Element Nanoparticles in Macrophages and the Involvement of Membrane Damage. [Abstract]2017 Dec 5;51(23):13938-13948. PMID: 29121463 -
Cancer Lett
Succinate dehydrogenase B palmitoylation promotes T cell exhaustion through the H3K27ac-PD1 axis in pancreatic cancer. [Abstract]2026 Apr 1:642:218277. PMID: 41577075 -
Cancer Lett
Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B. [Abstract]2022 Jun 1:535:215629. PMID: 35278612 -
Free Radic Biol Med
PGAM5 aggravated doxorubicin-induced cardiotoxicity by disturbing mitochondrial dynamics and exacerbating cardiomyocytes apoptosis. [Abstract]2025 Apr 23:S0891-5849(25)00247-3. PMID: 40280314 -
J Anim Sci Biotechnol
AMBRA1 activation alleviates zearalenone-induced swine testicular cell ferroptosis by facilitating mitophagy. [Abstract]2026 Mar 14;17(1):49. PMID: 41826991 -
Cell Rep
Menin orchestrates macrophage reprogramming to maintain the pulmonary immune homeostasis. [Abstract]2025 Jan 15;44(1):115219. PMID: 39817905 -
Cell Rep
2021 Nov 2;37(5):109931. PMID: 34731621 -
Br J Pharmacol
7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. [Abstract]2025 May;182(10):2310-2331. PMID: 40038493 -
Int J Oncol
Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. [Abstract]2019 Jul;55(1):331-339. PMID: 31180536 -
Pharmaceuticals (Basel)
Toosendanin Induces Hepatocyte Damage by Inhibiting Autophagic Flux via TFEB-Mediated Lysosomal Dysfunction. [Abstract]2022 Dec 3;15(12):1509. PMID: 36558960
Pepstatin Ammonium purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2022 Dec 3;15(12):1509. [Abstract]
TSN (10 μM), Baf (0.5 μM), and E64D (25 μM) plus pepstatin A (50 μM; E + P ) treatment significantly inhibits the degradation ability of lysosomes (in HepG2 cells and L02 cells; medium for 6 h).
-
Eur J Pharmacol
Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo. [Abstract]2022 Apr 5:920:174823. PMID: 35157912 -
Protein Sci
Distinct substrate specificities of the three catalytic subunits of the Trichomonas vaginalis proteasome. [Abstract]2024 Dec;33(12):e5225. PMID: 39589076 -
Int J Antimicrob Agents
2019 Dec;54(6):814-819. PMID: 31479744 -
Mol Med Rep
Hyperoside decreases the apoptosis and autophagy rates of osteoblast MC3T3‑E1 cells by regulating TNF‑like weak inducer of apoptosis and the p38mitogen activated protein kinase pathway. [Abstract]2019 Jan;19(1):41-50. PMID: 30387825 -
PLoS Pathog
HBV p22-interacting protein C1QBP inhibits viral replication through impeding nucleocapsid formation and nuclear import. [Abstract]2025 Oct 17;21(10):e1013581. PMID: 41105696 -
Mol Pharm
Saponin and Ribosome-Inactivating Protein Synergistically Trigger Lysosome-Dependent Apoptosis by Inhibiting Lysophagy: Potential to Become a New Antitumor Strategy. [Abstract]2024 May 9. PMID: 38722865 -
PLoS Pathog
The HN protein of Newcastle disease virus induces cell apoptosis through the induction of lysosomal membrane permeabilization. [Abstract]2024 Feb 14;20(2):e1011981. PMID: 38354122 -
Structure
2025 Dec 4;33(12):2049-2057.e5. PMID: 40914153 -
BBA Adv
Lysosomal membrane permeabilization is involved in CYP2E1-induced apoptosis in hepatocellular carcinoma cells. [Abstract]2026 May 16:9:100194. PMID: 42211167 -
FASEB J
PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIP-HSP70-BAG3 complex and the aggregation of ubiquitinated proteins. [Abstract]2022 Jan;36(1):e22121. PMID: 34951719 -
Immunotargets Ther
The Effects of M2 Macrophages-Derived Exosomes on Urethral Fibrosis and Stricture in Scar Formation. [Abstract]2025 Mar 4:14:151-173. PMID: 40061513 -
J Virol
Coxsackievirus A6 2C protein antagonizes IFN-β production through MDA5 and RIG-I depletion. [Abstract]2023 Nov 30;97(11):e0107523. PMID: 37847581 -
J Virol
Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues. [Abstract]2021 Nov 23;95(24):e0153721. PMID: 34550769 -
PLoS Genet
2025 Jul 10;21(7):e1011794. PMID: 40638681 -
Toxicol Appl Pharmacol
Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. [Abstract]2018 Oct 1;356:159-171. PMID: 30086361 -
Arch Biochem Biophys
Handelin protects human skin keratinocytes against ultraviolet B-induced photodamage via autophagy activation by regulating the AMPK-mTOR signaling pathway. [Abstract]2023 Jul 15:743:109646. PMID: 37225010 -
Biochem Biophys Res Commun
Structural insights into the allosteric effects of the antiepileptic drug topiramate on the CaV2.3 channel. [Abstract]2024 Jun 15:725:150271. PMID: 38901222 -
Biochem Bioph Res Co
Selective binding of mitophagy receptor protein Bcl-rambo to LC3/GABARAP family proteins. [Abstract]2020 Sep 10;530(1):292-300. PMID: 32828302 -
Biol Pharm Bull
Inhibition of Stearoyl-CoA Desaturase 1 Potentiates Anti-tumor Activity of Amodiaquine in Non-small Cell Lung Cancer. [Abstract]2022 Apr 1;45(4):438-445. PMID: 35110426 -
STAR Protoc
Protocol for reconstituting enzymatic activities for ultra-large histone methyltransferases NSD1 and SETD2 using a baculovirus expression system. [Abstract]2025 Jul 18;6(3):103963. PMID: 40684435 -
-
-
-
-
Solvant et solubilité
DMSO : 25 mg/mL (35.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.96 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Umezawa H, et al. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970 May;23(5):259-62. [Content Brief]
[2]. Seelmeier S, et al. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4226 mL | 7.1132 mL | 14.2264 mL | 35.5659 mL |
| 5 mM | 0.2845 mL | 1.4226 mL | 2.8453 mL | 7.1132 mL | |
| 10 mM | 0.1423 mL | 0.7113 mL | 1.4226 mL | 3.5566 mL | |
| 15 mM | 0.0948 mL | 0.4742 mL | 0.9484 mL | 2.3711 mL | |
| 20 mM | 0.0711 mL | 0.3557 mL | 0.7113 mL | 1.7783 mL | |
| 25 mM | 0.0569 mL | 0.2845 mL | 0.5691 mL | 1.4226 mL | |
| 30 mM | 0.0474 mL | 0.2371 mL | 0.4742 mL | 1.1855 mL |
Pepstatin Ammonium Related Classifications
HY-P0018B Related Classifications
Powered by Bioz